TML, which is generally high in bladder cancer 151, 152, has been correlated to bladder cancer anti‐PD‐1/PD‐L1 immunotherapy responses 61, 73, 75, although with an exception of a study with limited samples 79. This evidence concerns the gene PDCD1 and urinary bladder cancer.